發(fā)布時間：2018-05-02 08:36

  本文選題：強志散 + 多發(fā)性抽動癥��； 參考：《山東中醫(yī)藥大學》2016年碩士論文

【摘要】：目的:通過強志散治療多發(fā)性抽動癥(腎志不足型)患兒在抽動類型、頻度、強度以及對行為影響程度方面與西藥硫必利觀察比較,客觀評價強志散的有效性,并結合動物實驗,初步探究強志散對腦組織DA、NE的干預機制,為志意辨證理論修復完善提供參考。方法:1.臨床部分:將符合納入標準的60例患兒隨機分為強志散組和硫必利組,每組30例,強志組口服強志散湯劑,硫必利組口服硫必利。治療24周,隨訪24周。觀察兩組治療前后總療效、運動性抽動、發(fā)聲性抽動以及抽動的類型、頻率、強度、復雜程度、對生活干擾程度的療效、不良反應、安全性和遠期療效。2.實驗部分:40只SD大鼠隨機分為對照組、模型組、硫必利組、強志散組,每組10只。通過腹腔注射IDPN,300mg/kg,1次/d,連續(xù)7d,建立TS大鼠模型。強志散組按照5g/kg劑量灌服免煎顆粒,硫比利組按照25mg/kg劑量灌服硫必利,其余二組同時灌服等劑量生理鹽水。連續(xù)灌服4周。觀察大鼠體重及運動行為變化并檢測腦組織DA、NE含量。結果:1.臨床部分:在改善總體抽動、運動抽動、抽動頻率、抽動強度、對生活干擾程度方面,強志散療效優(yōu)于硫必利(p0.05)。在改善發(fā)聲抽動、抽動類型、復雜程度方面,強志散與硫必利療效相當(p0.05)。在中醫(yī)臨床癥候改善方面,強志散明顯優(yōu)于硫必利(p0.01)。2.實驗部分:強志散組大鼠腦組織DA、NE含量較硫必利組明顯降低(p0.05)。結論:強志散臨床治療多發(fā)性抽動癥(腎志不足型)安全有效,降低大鼠腦內DA、NE含量可能是強志散治療抽動癥的作用機制之一。
[Abstract]:Objective: to evaluate the effectiveness of Qiangzhi Powder in treating children with multiple tic syndrome (deficiency of renal history) in terms of twitch type, frequency, intensity and the degree of influence on behavior, and to evaluate the effectiveness of Qiangzhi San objectively compared with that of western medicine tiapride. Combined with animal experiments, the intervention mechanism of Qiangzhi San on brain tissue DANNE was preliminarily explored, which provided a reference for the improvement of the theory of Yiyi differentiation of symptoms and signs. Method 1: 1. Clinical part: 60 children who met the inclusion criteria were randomly divided into Qianzhisan group and tiapride group with 30 cases in each group. Qiangzhi group took Qianzhisan decoction and Tiapride group orally took tiapride. The patients were followed up for 24 weeks. The types, frequency, intensity, complexity, adverse reaction, safety and long term effect of the two groups were observed before and after treatment, and the types, frequency, intensity, complexity, adverse reactions, safety and long-term efficacy of the two groups were observed. In the experiment, 40 Sprague-Dawley rats were randomly divided into control group, model group, tiapride group and Qiangzhi powder group, with 10 rats in each group. The model of TS rats was established by intraperitoneal injection of IDPN 300 mg / kg / d for 7 days. Qiangzhi San group was treated with 5g/kg, thiapride group was given thiapride according to 25mg/kg dose, and the other two groups were given the same dose of normal saline at the same time. Continuous administration for 4 weeks. The changes of body weight and motor behavior were observed and the content of DANNE in brain tissue was measured. The result is 1: 1. Clinical part: Qiangzhi San was superior to tiapride p0.05 in improving total twitch, movement twitch, twitch frequency, twitch intensity and interference degree of life. In improving phonation twitching, twitch type and complexity, Qianzhi San has the same curative effect as thiapride. In the aspect of improvement of TCM clinical symptoms, Qiangzhi San is obviously superior to tiapride p0.01. 2. Experimental part: the content of DAN in brain tissue of Qiangzhi San group was significantly lower than that of tiapride group. Conclusion: Qiangzhi Powder is safe and effective in the treatment of multiple tic syndrome (deficiency of renal information). Reducing the content of DANe in rat brain may be one of the mechanisms of Qiangzhi Powder in treating tic.
【學位授予單位】：山東中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R249;R277.7

【參考文獻】

相關期刊論文 前10條

1 孫理軍;孫瑜[,;張琪;孫耀光;王興;王曉棣;;基于腎藏志理論的腎虛質大鼠生長發(fā)育與NMDA受體表達實驗研究[J];遼寧中醫(yī)藥大學學報;2016年01期

2 張紅;黃海忠;林國棟;;利培酮與阿立哌唑治療兒童抽動障礙的隨機對照研究[J];臨床薈萃;2015年12期

3 孫凌蓉;;針灸治療兒童抽動癥30例[J];實用中醫(yī)藥雜志;2015年11期

4 李清清;李葆明;;大鼠前扣帶回皮層腦源性神經(jīng)營養(yǎng)因子參與恐懼記憶的形成（英文）[J];生理學報;2015年05期

5 方瓊;陳瑯;陳巧彬;楊芳;;阿立哌唑治療兒童抽動障礙療效和安全性的Meta分析[J];中國當代兒科雜志;2015年07期

6 崔遠武;張連城;李強;王凱;張玉蓮;;中醫(yī)“腎腦系統(tǒng)”的初步構建[J];天津中醫(yī)藥;2015年03期

7 胡敏;顏剛;;可樂定緩釋片治療抽動癥的療效及不良反應的初步研究[J];中國兒童保健雜志;2014年12期

8 李霽;韓斐;;韓斐運用中醫(yī)心主神明論診治抽動障礙思路及經(jīng)驗[J];遼寧中醫(yī)藥大學學報;2014年08期

9 張鵬;陳地靈;林勵;林輝;鄧韜;吳俊生;;巴戟天水提液對自然衰老小鼠腦組織中單胺類神經(jīng)遞質含量的影響[J];醫(yī)學研究雜志;2014年06期

10 劉俠;;氟哌啶醇治療兒童抽動障礙不良反應20例臨床分析[J];內蒙古中醫(yī)藥;2014年02期

，

本文編號：1833181